Telo Genomics Corp. News Releases

Telo Genomics Grants Stock Options

Tue, 04 Aug 2026 06:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces the grant of stock options (the "Options") pursuant to its stock option plan to purchase up to an aggregate of 3,300,000 common shares of the Company, subject to TSX Venture Exchange approval, of which 2,500,000...

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Thu, 16 Jul 2026 07:00:00 -0400

Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of...

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Thu, 09 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM")."This filing...

Telo Genomics Announces Termination of Investor Relations Agreement

Fri, 26 Jun 2026 20:58:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties...

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Tue, 14 Apr 2026 07:00:00 -0400

Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are...

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Tue, 31 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered into a...

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mon, 09 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures")...

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Fri, 27 Feb 2026 15:32:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from up to $1,200,000 to up to...

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Wed, 18 Feb 2026 07:00:00 -0500

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private...

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Thu, 29 Jan 2026 08:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately. Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has over three decades of...